FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

Posted: September 27, 2024 at 2:51 am

REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

See more here:
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

Related Posts